Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies

NCT03166215 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03166215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03166215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Completed
Start date
August 17, 2017
Completion date
September 19, 2018
Enrollment
18 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and/or epileptic encephalopathies